Early Diagnostics of Neurodegenerative Diseases

Oliver Bannach is „Düsseldorf Citizen of the Year 2017“

Oliver Bannach, designated CEO of attyloid, was recently awarded „Düsseldorf Citizen of the Year 2017“ to acknowledge his research on Alzheimer’s disease diagnostics as well as his spin-off activities.

ISO 9001:2015 certification

attyloid announces that its mother institution ICS-6 of Forschungszentrum Jülich has recently obtained ISO 9001:2015 quality certification.

BioEurope Berlin 2017

Meet attyloid at the BIO.NRW booth

Scientific Background / Technology

Alzheimer’s disease is a neurodegenerative disorder with limited therapeutic and diagnostic options. The failure of late-stage clinical trials has been mainly attributed to a lack of a direct biomarker that can be used for selection of non-symptomatic patients, therapy monitoring, target engagement and outcome measure. Among the most promising biomarker candidates are Aβ oligomers, which are the key players in the disease pathology. We have developed the sFIDA platform technology for ultra- sensitive quantitation of Aβ oligomers in body liquids.

sFIDA

sFIDA stands for surface-based fluorescence intensity distribution analysis. The assay uses a combination of aggregate-binding antibodies and fluorescence microscopy imaging. First, protein aggregates are captured from the sample and fixed to a glass sur- face. After unbound sample components are removed, detection antibodies labeled with two fluorescent dyes are added. A laser focus scans the surface and the highly decorated aggregates show bursts of fluorescent light in two color channels.

In first proof of concept studies, sFIDA allowed clear differentiation between samples from diseased and healthy donors. Moreover, the readout correlated with the severity of cognitive deficits. The assay is currently in the process of validation and optimization for the demands of high-throughput measurements.

attyloid will offer its proprietary sFIDA technology for early diagnostics of neurodegenerative diseases

ICS-6: Structural Biochemistry

Research at the Forschungszentrum Jülich’s aims for a fundamental understanding of disease-related proteins at the atomic and molecular level. A defining characteristic is the combination of basic research in structural biology and applied research for new diagnostic and therapeutic approaches to neurodegenerative diseases.

Our Profile

High resolution structural biology for molecular biomedicine and biotechnology

  • Innovations in diagnostics and therapy for ending Alzheimer’s disease
  • Exploring diagnostics and therapy for other prion diseases, e. g. ALS, PD and HD

About Us

attyloid is a spin-off project from Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. attyloid will offer its proprietary sFIDA technology for early diagnostics of neurodegenerative diseases, such as Alzheimer’s or Parkinson’s disease. The sFIDA platform technology quantitates small protein oligomers as fluid biomarkers and will be applied in clinical studies and, once a causal therapy is available, for routine diagnostics.

Forschungszentrum Jülich

Forschungszentrum Jülich is located in Jülich about 50 minutes from Düsseldorf Airport and 60 minutes from Düsseldorf City. With over 5,800 employees, Forschungszentrum Julich – a member of the Helmholtz Association – is one of the largest interdisciplinary research centres in Europe, pursuing cutting- edge interdisciplinary research on pressing issues facing society today in the fields of energy and environment, information and brain research.

Heinrich Heine University of Düsseldorf

Heinrich Heine University of Düsseldorf is one of the younger higher education institutions in the state of North Rhine-Westphalia – founded in 1965. Today around 30,000 students study at a modern campus under conditions ideally suited to academic life. The university departments enjoy an excellent reputation due to an exceptionally high number of collaborative research centres.

Founders and Idea

Since 2014 our project has been supported by the VIP-Program of the German Federal Ministry of Education. In 2016 we obtained funding by the Helmholtz Enterprise Program and by Start-up NRW to turn this diagnostic approach into a scientific spin-off company.

attyloid draws on a strong team of founders with expertise in Life Science, Health Care and Corporate Development.

Dr. Oliver Bannach

Dr. Oliver Bannach

designated CEO

 Dr. Andreas Kulawik

Dr. Andreas Kulawik

designated CPO

Dr. Christian Zafiu

Dr. Christian Zafiu

designated CSO

Prof. Dr. Dr. Detlev Riesner

Prof. Dr. Dr. Detlev Riesner

SAB

Prof. Dr. Dieter Willbold

Prof. Dr. Dieter Willbold

SAB

Get in Touch

9 + 11 =

attyloid spin-off project

Forschungszentrum Jülich
52428 Jülich
Germany

Mail: info@attyloid.com
Fon: +49 (0) 2461 61-2100